NeuroBo Pharmaceuticals (NRBO)
(Delayed Data from NSDQ)
$3.23 USD
+0.09 (2.87%)
Updated Apr 29, 2024 03:59 PM ET
After-Market: $3.23 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NRBO 3.23 +0.09(2.87%)
Will NRBO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NRBO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NRBO
The Zacks Analyst Blog Highlights Molina Healthcare, Dr. Reddy's Laboratories and NeuroBo Pharmaceuticals
4 Undervalued Medical Stocks to Buy Amid High Market Volatility
NRBO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Want to Shrug Off Volatility? Buy 3 Medical Growth Stocks
Here's Why NeuroBo Pharmaceuticals, Inc. (NRBO) Could be Great Choice for a Bottom Fisher
Other News for NRBO
NeuroBo Pharmaceuticals management to meet with Maxim Group
NeuroBo Pharmaceuticals management to meet with Maxim Group
NeuroBo Pharmaceuticals doses first patient in Phase 1 DA-1726 trial
NeuroBo Pharmaceuticals files for $150M mixed shelf
NeuroBo Pharmaceuticals files $150M mixed securities shelf